Contract facts
SBASBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES is a federal SBA award for Nih Nci held by Cellsight Technologies Inc. Estimated value $2M ($2M obligated). Current period of performance ends Sep 15, 2026. Last award drew 2 bidders. Place of performance: SAN FRANCISCO CA. Related solicitation 75N91021R00068.
SBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES
Recompete timing
PublicCurrent PoP ends Sep 15, 2026 (26 days remaining). Agencies typically plan 12–18 months ahead — at 0.9 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordCellsight Technologies Inc — — obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N91022C00015?
75N91022C00015 (SBIR PHASE II - TOPIC 396) is a Nih Nci award with a potential value of $2M, currently held by Cellsight Technologies Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N91022C00015?
Nih Nci awarded 75N91022C00015 to Cellsight Technologies Inc (potential $2M).
Who is the incumbent on 75N91022C00015?
Cellsight Technologies Inc is the incumbent with — across 1 related awards in SCOUT’s public footprint. The current period of performance ends Sep 15, 2026.
When does Cellsight Technologies Inc’s 75N91022C00015 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 15, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.